The global PARP Inhibitor Market is estimated to be valued at USD 6.60 Bn in 2022 and is expected to exhibit a CAGR of 13.09% over the forecast period 2023-2031, as highlighted in a new report published by Coherent Market Insights.

A) Market Overview:
PARP inhibitors are a class of drugs that inhibit the enzyme poly (ADP-ribose) polymerase (PARP). These inhibitors have gained significant attention in the field of oncology due to their ability to target cancer cells ... Read more

PARP inhibitors are emerging as an important therapeutic class of drugs for the treatment of various cancers like ovarian cancer, breast cancer, and prostate cancer. PARP inhibitors act by inhibiting the DNA repair enzyme called Poly (ADP-ribose) polymerase. The inhibition of PARP enzyme prevents cancer cells from repairing DNA damage caused by chemotherapy or radiation therapy. This leads to cell death in cancer cells. PARP inhibitors are increasingly being used as a maintenance therapy for ... Read more